On defending science and reason

🌟 Join the CPCR Archives Project at Johns Hopkins! 🌟 We’re creating the world’s largest digital collection of published firsthand accounts of psychedelic experience across cultures. If you’re interested in joining our team, please reach out to Jeremy Scott at [email protected]

We analyzed 2 decades of materials used in psilocybin trials. We examined how “set and setting” is communicated to participants pre- psychedelic sessions. Most content is about bio, psych, and social safety–but we also draw attention to some potentially unintentional expectancies

A new review of prep materials from the past two decades led by CPCR Faculty David Yaden (@existwell) shows psilocybin trial prep materials strongly emphasize safety yet can also shape participant expectations—highlighting a delicate balance between ensuring well-being and

All antipsychotics can cause OCD, but it is mot common on clozapine. 20% of patients develop new onset OCD on clozapine, from new review: pubmed.ncbi.nlm.nih.gov/39849391 How? Serotonin 5-HT2A inverse agonist, as is iloperidone, olanzapine, paliperidone, risperidone.

Excited to announce a clinic for individuals experiencing difficulties following a psychedelic experience. I believe this is the first clinic of its kind in the US and is right here at Johns Hopkins Medicine, where we aim to learn about & address the benefits & risks of psychedelics 🧵

Putin is the dictator. Zelensky is not. Putin’s Russia invaded Ukraine. After kidnapping, murdering and raping hundreds of thousands in this senseless war, rewarding Putin and Russia would be both a betrayal of humanity and a green light for more aggression.

We are hiring a new postdoc! This postdoctoral fellowship is an excellent opportunity to gain experience (1) managing the operation of clinical drug trials focused on the treatment of PTSD, (2) learning to conduct Psilocybin Therapy, (3) producing new knowledge (data analysis,

Live from the Senate floor. x.com/i/broadcasts/1…

🚨Please apply to this postdoc opportunity! (and share) Deadline: April 22nd 🌎 We're receiving EXCELLENT applications & would like to review more, particularly those with MD/PhD dual degrees. In cases of alignment with other related opportunities, we will refer candidates––

With Caleigh Propes (she/her), Marianna Graziosi, Kyle Patch & David B. Yaden, we reviewed ICDs from psilocybin clinical trials across the U.S., and provided a systematic qualitative description of these ICDs.

Most definitely the most comprehensive review of the state of the science so far! Personally, love the summary of research on awe :]